News Merck gets stuck on Proxygen’s molecular glue degraders Proxygen has added another big pharma company to its list of partners, with Merck & Co the latest to be snared by its molecular glue degrader technology.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.